Page 68 - MemoriaCIBER-2018ENG

68
neutrophils in alcoholic hepatitis. Aguilar- Bravo B,Rodrigo-Torres D,Ariño S,Coll M, Pose E, Blaya D, Graupera I, Perea L, Vallverdú J, Rubio-Tomás T, Dubuquoy L, Armengol C, Lo Nigro A, Stärkel P, Mathurin P, Bataller R, Caballería J, Lozano JJ, Ginès P, Sancho-Bru P. Hepatology 2018.doi: 10.1002/hep.30472.
• Generation of Hepatic Stellate Cells from Human Pluripotent Stem Cells Enables In Vitro Modeling of Liver Fibrosis. Coll
Chronic Hepatitis B platform. CIBERHEP
Coordinator:
David Tabernero Caellas
CIBERHEP chronic hepatitis B platform is a cooperation scheme between the CIBER and the Asociación Española para el Estudio del Higado (AEEH). At the present time this is the main database for patients being treated for chronic hepatitis B in Spain, focussing mainly on the
e-CATCH
Coordinator:
Jordi Bruix Tudó
The e-CATCH platform has worked in two areas:
The service for advice on diagnosis and treatment of liver cancer was kept up with a limited number of consultations (average of 1 per month).
M, Perea L, Boon R, Leite SB, Vallverdú J, Mannaerts I,Smout A,El Taghdouini A,Blaya D, Rodrigo-Torres D, Graupera I, Aguilar-Bravo B, Chesne C, Najimi M, Sokal E, Lozano JJ, van Grunsven LA, Verfaillie CM, Sancho-Bru P. Cell.Stem.Cell 2018 Jul 5;23(1):101-113.
Our group continues to collaborate in new projects with great recognition for its work, since two new FIS were financed (PI18/00383, PI18/01125) this year with CIBER centres.
follow-up of patients in antiviral treatment with entecavir (ETV) and tenofovir (TDF). 27 centres from 9 different autonomous communities (regional administrative areas) continue to take part in this and 1516 patients have been registered, with data from a total number of 15,056 visits available for analysis. In 2018 we continued with the review of patients already registered in the database, a process which was started in 2017,
in which visits with incomplete or improperly compiled data were removed. This has entailed little activity this year. At the present time this platform’s objectives are being reviewed to decide on its possible future reorientation.
The growth in its activity was due to using
the platform as an instrument for centralised assessment of images in the context of clinical trials promoted by the researchers.
This allows a blind evaluation of patients’ evolution and a validation of what was reported in descriptive studies of cohorts in which a uniform reading is essential.
CIBEREHD | ANNUAL REPORT 2018